Exisulind
- Generic Name
- Exisulind
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H17FO4S
- CAS Number
- 59973-80-7
- Unique Ingredient Identifier
- K619IIG2R9
- Indication
Investigated for use/treatment in adenomatous polyposis coli, lung cancer, prostate cancer, colon polyps, Barrett's esophagus disease, and pediatric indications.
- Associated Conditions
- -
- Associated Therapies
- -
Neoadjuvant Exisulind in Treating Patients Who Are Undergoing Radical Prostatectomy for Stage II or Stage III Prostate Cancer
Phase 2
Completed
- Conditions
- Prostate Cancer
- First Posted Date
- 2004-03-09
- Last Posted Date
- 2013-06-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 130
- Registration Number
- NCT00078910
- Locations
- 🇺🇸
Mayo Clinic Cancer Center, Rochester, Minnesota, United States
🇺🇸Mayo Clinic Scottsdale, Scottsdale, Arizona, United States
🇺🇸Mayo Clinic - Jacksonville, Jacksonville, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath